Loading the records…
Loading the records…
Ellie's Law (HR2678) is an early-stage authorization bill directing NINDS to research unruptured intracranial aneurysms. It authorizes zero dollars, has no funding appropriation, and has only been referred to committee. Market impact is negligible in the near term for device and research tool providers like MDT, TMO, ILMN, and DGX, as no actual spending exists and the legislative path is years from completion.
Key takeaways, market implications, full AI analysis, and connected signals are available to HillSignal members.
Already have an account? Log in
No near-term market impact. MDT at $79.22 (approaching 52-week low of $78.91) has been affected by broader medtech headwinds, not this bill. TMO at $469.51 and ILMN at $123.58 trade on earnings and sector trends. DGX at $192.76 is similarly driven by healthcare utilization cycles, not early-stage research authorization bills. Investors should not allocate capital based on Ellie's Law until it advances through committee and a specific funding amount is attached.
Ellie's Law (HR2678) was introduced on April 7, 2025, and referred to the House Committee on Energy and Commerce. The bill directs the National Institute of Neurological Disorders and Stroke (NINDS) to conduct and support comprehensive research on unruptured intracranial aneurysms, develop diagnostics and treatments, and create a public education campaign. Critically, the bill authorizes no specific dollar amount — it is a policy authorization that sets a program in law but requires a separate appropriations bill to allocate any actual funds. With 46 bipartisan cosponsors and a companion bill (S1609) in the Senate, momentum is building, but the bill remains at the very earliest legislative stage with no committee hearings or markups yet scheduled.
The money trail is zero. Authorization bills set policy ceilings but do not allocate money. Actual funding for NINDS aneurysm research would require a future appropriations bill — and even then, the amount is unspecified. The structural impact on the medical device and diagnostics sectors is purely directional and long-dated: if future appropriations materialize, NINDS could award research grants that accelerate development of neurovascular devices (MDT's flow diverters, coils) and diagnostic tools (ILMN sequencing for genetic risk, TMO research equipment, DGX lab testing). But no contracts or revenues are guaranteed by this bill.
Market data as of April 30, 2026 shows MDT at $79.22 (down 8.57% in 30 days, approaching 52-week low of $78.91), ISRG at $449.95 (down 2.39% in 30 days), TMO at $469.51 (down 4.48% in 30 days), ILMN at $123.58 (up 0.26% in 30 days), and DGX at $192.76 (down 1.64% in 30 days). These price movements reflect broader sector trends and company-specific factors, not any impact from Ellie's Law, which is too early-stage and unfunded to affect valuations.
Remaining legislative path: referral to committee (current), subcommittee review, committee markup, House floor vote, Senate companion (S1609) committee markup and floor vote, conference committee (if different versions), presidential signature, then a separate appropriations process. Even under optimistic scenarios, any tangible market impact is 2-4 years away.
Cross-referenced against federal contracts, SEC insider filings & congressional trade disclosures
Some confirming evidence found across public data sources
Matched on shared policy language across AI analyses, with ticker & timing weight
MERCK SHARP & DOHME LLC: $1.8B Department of Health and Human Services Contract Vehicle
OHIO DEPARTMENT OF MEDICAID: $28.2B Department of Health and Human Services Grant
MULTIPLE RECIPIENTS: $1.2B Department of Health and Human Services Federal Award
MULTIPLE RECIPIENTS: $2.1B Department of Health and Human Services Federal Award
MULTIPLE RECIPIENTS: $4.6B Department of Health and Human Services Federal Award
MULTIPLE RECIPIENTS: $4.6B Department of Health and Human Services Federal Award
MULTIPLE RECIPIENTS: $4.0B Department of Health and Human Services Federal Award
MULTIPLE RECIPIENTS: $1.4B Department of Health and Human Services Federal Award
Executive orders & memoranda affecting the same sectors or companies
This executive order establishes a Women's Health Division within the NIH to coordinate and accelerate research on understudied women's health conditions, and creates a White House Women's Health Task Force to drive policy reforms and translation of research into clinical practice across federal agencies. It directs specific agencies to prioritize research, data collection, and translation into prevention, diagnosis, and treatment, with a focus on all life stages from infancy through aging.
This executive order directs the Secretaries of State, Labor, and Homeland Security to coordinate with Commerce, Education, and the SBA when processing H-1B petitions, and requires them to consider whether the employer has engaged in layoffs of similarly situated U.S. workers within the past year. It also orders the Labor Department to review past labor condition applications for potential enforcement actions against sponsoring employers, effectively tightening scrutiny on H-1B usage, especially by outsourcing firms.
This proclamation orders the Secretaries of War and Veterans Affairs to mandate rapid, ongoing digital sharing of military personnel and medical records, deploy AI-powered tools for benefits applications, and update existing IT contracts for interoperability. It also requires the Transition Assistance Program to connect separating service members to specific jobs or training programs before discharge.
Free — no credit card
HillSignal scores every Congressional bill, federal contract, and insider filing for market impact and emails you the high-conviction ones — free, no credit card.
Weekly digest — the congressional activity that actually moved markets that week, in plain English. Free, one email.
Free forever plan · No credit card · Unsubscribe in one click
Want the live terminal too? Create a free account →